Therapeutic drug delivery by genetically modified Lactococcus lactis

Annals of the New York Academy of Sciences

Volumn 1072, Issue , 2006, Pages 176-186

  Steidler, Lothar ^a   Rottiers, Pieter ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Colitis; Containment; Delivery; Expression; Lactococcus

Indexed keywords

CYTOKINE; DNA; INTERLEUKIN 10; THYMIDYLATE SYNTHASE;

ANTIBODY TITER; COLITIS; CONFERENCE PAPER; CYTOKINE PRODUCTION; DNA DAMAGE; DNA MODIFICATION; ENTERITIS; GENE; IMMUNE SYSTEM; LACTOCOCCUS LACTIS; NONHUMAN; PROTEIN EXPRESSION; THYA GENE;

LACTOCOCCUS; LACTOCOCCUS LACTIS; LOTUS;

EID: 33749022511     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1326.031     Document Type: Conference Paper

References (53)

1. AHMED, F.E. 2003. Genetically modified probiotics in foods. Trends Biotechnol. 21: 491-497.
2. KLEEREBEZEM, M. & J. HUGENHOLTZ. 2003. Metabolic pathway engineering in lactic acid bacteria. Curr. Op. Biotechnol. 14: 232-237.
3. SEEGERS, J.F. 2002. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol. 20: 508-515.
4. NOUAILLE, S., L.A. RIBEIRO, A. MIYOSHI, et al. 2003. Heterologous protein production and delivery systems for Lactococcus lactis. Genet. Mol. Res. 2: 102-111.
5. WELLS, J.M., P.W. WILSON, P.M. NORTON, et al. 1993. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. 8: 1155-1162.
6. NORTON, P.M., J.M. WELLS, H.W BROWN, et al. 1997. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 15: 616-619.
7. ROBINSON, K., L.M. CHAMBERLAIN, K.M. SCHOFIELD, et al. 1997. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. 15: 653-657.
8. MANNAM, P., K.F. JONES & B.L. GELLER. 2004. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with streptococcus pyogenes. Infect. Immun. 72: 3444-3450.
9. STEIDLER, L., J.M. WELLS, A. RAEYMAEKERS, et al. 1995. Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis. Appl. Environ. Microbiol. 61: 1627-1629.
10. STEIDLER, L., K. ROBINSON, L. CHAMBERLAIN, et al. 1998. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect. Immun. 66: 3183-3189.
11. STEIDLER, L., W. HANS, L. SCHOTTE, et al. 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355.
12. SCHOTTE, L., L. STEIDLER, J. VANDEKERCKHOVE, et al. 2000. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb. Technol. 27: 761-765.
13. RONG, Y., N. LEE & S.M. LIANG. 1992. Analysis of IL-2 functional structure by multiple cysteine substitutions. Biochem. Biophys. Res. Commun. 188: 949-955.
14. ZHANG, J.G., J.M. MATTHEWS, L.D. WARD, et al. 1997. Disruption of the disulfide bonds of recombinant murine interleukin-6 induces formation of a partially unfolded state. Biochemistry 36: 2380-2389.
15. WINDSOR, W.T., R. SYTO, A. TSARBOPOULOS, et al. 1993. Disulfide bond assignments and secondary structure analysis of human and murine interleukin 10. Biochemistry 32: 8807-8815.
16. CHADWICK, M.P., F.E. MAY & B.R. WESTLEY. 1995. Production and comparison of mature single-domain 'trefoil' peptides pNR-2/pS2 Cys58 and pNR-2/pS2 Ser58. Biochem. J. 308: 1001-1007.
17. STEIDLER, L., S. NEIRYNCK, N. HUYGHEBAERT, et al. 2003. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21: 785-789.
18. VANDENBROUCKE, K., W. HANS, J. VAN HUYSSE, et al. 2004. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127: 502-513.
19. MERTENS, N., E. REMAUT & W. FIERS. 1995. Tight transcriptional control mechanism ensures stable high-level expression from T7 promoter-based expression plasmids. Biotechnology 13: 175-179.
20. GUISEZ, Y., J. DEMOLDER, N. MERTENS, et al. 1993. High-level expression, purification, and renaturation of recombinant murine interleukin-2 from Escherichia coli. Protein Expr. Purif. 4: 240-246.
21. DERYNCK, R., E. REMAUT, E. SAMAN, et al. 1980. Expression of human fibroblast interferon gene in Escherichia coli. Nature 287: 193-197.
22. STEIDLER, L., W. FIERS & E. REMAUT. 1996. Expression of human and murine interleukins in Lactococcus lactis. In Metabolism and Application of Lactic Acid Bacteria. B. Ray & F. Bozoglu, Eds.: 63-79. Springer-Verlag. Berlin-Heidelberg, New York.
23. DROUAULT, S., C. JUSTE, P. MARTEAU, et al. 2002. Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl. Environ. Microbiol. 68: 3166-3168.
24. CHANG, T.L., C.H. CHANG, D.A. SIMPSON, et al. 2003. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl. Acad. Sci. USA 100: 11672-11677.
25. BERMUDEZ-HUMARAN, L.G., P. LANGELLA, N.G. CORTES-PEREZ, et al. 2003. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect. Immun. 71: 1887-1896.
26. LING, P., M.K. GATELY, U. GUBLER, et al. 1995. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J. Immunol. 154: 116-127.
27. REPA, A., C. GRANGETTE, C. DANIEL, et al. 2003. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 22: 87-95.
28. LEHNER, T, J. CALDWELL & R. SMITH. 1985. Local passive immunization by monoclonal antibodies against streptococcal antigen I(II in the prevention of dental caries. Infect. Immun. 50: 796-799.
29. MICHALEK, S.M., R.L. GREGORY, C.C. HARMON, et al. 1987. Protection of gnotobiotic rats against dental caries by passive immunization with bovine milk antibodies to Streptococcus mutans. Infect. Immun. 55: 2341-2347.
30. KRUGER, C., Y. HU, Q. PAN, et al. 2002. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat. Biotechnol. 20: 702-706.
31. FIDEL, P.L., JR. & J.D. SOBEL. 1996. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin. Microbiol. Rev. 9: 335-348.
32. MEDAGLINI, D., C.M. RUSH, P. SESTINI, et al. 1997. Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice. Vaccine 15: 1330-1337.
33. MEDAGLINI, D., M.R. OGGIONI & G. POZZI. 1998. Vaginal immunization with recombinant gram-positive bacteria. Am. J. Reprod. Immunol. 39: 199-208.
34. DI FABIO, S., D. MEDAGLINI, C.M. RUSH, et al. 1998. Vaginal immunization of cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine 16: 485-492.
35. BENINATI, C., M.R. OGGIONI, M. BOCCANERA, et al. 2000. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol. 18: 1060-1064.
36. MAGLIANI, W., S. CONTI, F. DE BERNARDIS, et al. 1997. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15: 155-158.
37. POLONELLI, L. & G. MORACE. 1987. Production and characterization of yeast killer toxin monoclonal antibodies. J. Clin. Microbiol. 25: 460-462.
38. THOMPSON, C. & F. POWRIE. 2004. Regulatory T cells. Curr. Opin. Pharmacol. 4: 408-414.
39. BLUESTONE, J.A. & A.K. ABBAS. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257.
40. BRAAT, H., M.P. PEPPELENBOSCH & D.W. HOMMES. 2003. Interleukin-10-based therapy for inflammatory bowel disease. Exp. Op. Biol. Ther. 3: 725-731.
41. FEDORAK, R.N., A. GANGL, C.O. ELSON, et al. 2000. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482.
42. SCHREIBER, S. 2000. Genetics of inflammatory bowel disease: a puzzle with contradictions? Gut 47: 746-747.
43. VAN DEVENTER, S.J., C.O. ELSON & R.N. FEDORAK. 1997. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113: 383-389.
44. TILG, H., H. ULMER, A. KASER, et al. 2002. Role of IL-10 for induction of anemia during inflammation. J. Immunol. 169: 2204-2209.
45. FOLIGNE, B., S. NUTTEN, L. STEIDLER, et al. 2006. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. Dig. Dis. Sci. 51: 390-400.
46. TAUPIN, D. & D.K. PODOLSKY. 2003. Trefoil factors: initiators of mucosal healing. Nat. Rev. Mol. Cell. Biol. 4: 721-732.
47. POULSEN, S.S., J. THULESEN, L. CHRISTENSEN, et al. 1999. Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut 45: 516-552.
48. THIM, L. & E. MORTZ. 2000. Isolation and characterization of putative trefoil peptide receptors. Regul. Pept. 90: 61-68.
49. TAN, D., H. CHEN, P. LIU, et al. 2000. Prostanoids mediate the protective effect of trefoil factor 3 in oxidant-induced intestinal epithelial cell injury: role of cyclooxygenase-2. J. Cell. Sci. 113: 2149-2155.
50. RODRIGUES, S., E. VAN AKEN, S. VAN BOCXLAER, et al. 2003. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor S. signaling. FASEB J. 17: 7-16.
51. MIZUNO, H., C. SAKAMOTO, K. MATSUDA, et al. 1997. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112: 387-397.
52. EHRLICH, K., S. PLATE, T. STROFF, et al. 1998. Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection: role of cyclooxygenase-2. AJP Gastrointest. Liver Physiol. 274: G955-G964.
53. AHMAD, S.I., S.H. KIRK & A. EISENSTARK. 1998. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu. Rev. Microbiol. 52: 591-625.